Evicenter
P&T meetings

Zanzalintinib (XL092)

Metastatic colorectal cancer

Manufacturer
Exelixis
Regulatory submission
NDA submitted December 2025
Launch
Not announced
Last updated
65 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacokinetics

2 evidence topics · 3 sources

Pharmacokinetic half-life

“Zanzalintinib has a pharmacokinetic half-life of approximately one day, supporting once-daily dosing” (opens the source at this quote in a new tab)

Preliminary median terminal half-life

“21 hours” (opens the source at this quote in a new tab)